Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Chugai Plays It Safe with New 3-Year Plan on Consecutive Re-Pricing, Eyes 7-9% Annual EPS Growth
Chugai Pharmaceutical is targeting a compound annual growth rate (CAGR) of high single digits in core EPS under its new three-year business plan for 2019-2021, projecting milder growth than the previous term as it braces for three consecutive years of…
To read the full story
Related Article
- Chugai Ups Core EPS CAGR Target to “Around 30%”: 3-Year Biz Plan
January 31, 2020
- Chugai Running Offensive/Defensive Play towards EPS Growth Goal, Hemlibra Outpaces Target
August 9, 2019
- Chugai Nets 40%-Plus Profit Rise, but Keeps 3-Year EPS Target; President Nixes Avastin Biosame
July 26, 2019
- Chugai Renews Record Earnings in 2018 on New Drugs, Exports
February 1, 2019
BUSINESS
- FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
- Biomedix Takes Over Originator Data as Generics Face Supply, Information Challenge
February 13, 2026
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- Nxera Gets US$1.8 Million Early-Stage Milestone from Centessa
February 13, 2026
- Nxera Licenses GPCR Program to European VC-Backed Startup
February 13, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…